Tirzepatide MTD Demonstrates Cost-Effectiveness Versus Semaglutide MTD in Obesity Simulation Modeling Study

This analysis utilized a simulation modeling study design that incorporated data from Phase-3 clinical trials. The setting was defined from a United States societal perspective. The target population included individuals with obesity defined as a BMI of 30 kg/m or greater, or overweight defined as a BMI of 27 to less than 30 kg/m plus at least one obesity-related complication. Patients with type 2 diabetes were excluded from this cohort. The specific sample size of the underlying trial data was not reported in the available documentation.

The intervention evaluated was tirzepatide administered at the maximum-tolerated-dose. This was compared directly against semaglutide also administered at the maximum-tolerated-dose. The follow-up period focused on long-term clinical outcomes rather than short-term efficacy endpoints. The study aimed to determine the economic value and health benefits associated with each pharmacologic strategy within the specified population.

Primary outcomes centered on cost-effectiveness measured as cost per quality-adjusted life year. Per patient cost savings were observed where tirzepatide was less costly compared to semaglutide by $41,688. In terms of health utility, 0.506 QALYs gained were reported for the tirzepatide group. The incremental net health benefit was positive with a value of 0.784. These figures suggest a favorable economic profile for the intervention relative to the comparator.

Secondary outcomes assessed the development of specific comorbidities over the modeled time horizon. For type 2 diabetes, 70 fewer patients per 1,000 patients were projected to develop the condition with tirzepatide. Similarly, 10 fewer patients per 1,000 patients were projected to develop cardiovascular disease. Regarding obstructive sleep apnea, the direction indicated semaglutide was associated with 3.07 years per patient more living with moderate or severe obstructive sleep apnea compared to tirzepatide.

Safety and tolerability findings were not reported in the provided evidence summary. Adverse event rates, serious adverse events, and discontinuations were not reported. Consequently, the safety profile cannot be directly compared between the two agents based on this specific modeling output. Clinicians must rely on separate clinical trial data for safety assessments.

Methodological limitations include the study design being a simulation model rather than a randomized clinical trial reporting primary outcomes. Outcomes are modeled predictions rather than direct observed clinical trial outcomes. Uncertainty was assessed through sensitivity and scenario analyses. The sample size of the underlying SURMOUNT-5 trial is not specified in the abstract. These factors introduce uncertainty regarding the precision of the estimates. Generalizability may be limited by the specific assumptions inherent in the modeling process.

Clinical implications suggest tirzepatide at maximum-tolerated-dose is a cost-effective treatment option for individuals with obesity or overweight compared to semaglutide at maximum-tolerated-dose. This data supports consideration of tirzepatide for cost-conscious healthcare systems. However, the modeling nature requires cautious interpretation regarding real-world effectiveness.

Several questions remain unanswered regarding the long-term durability of these modeled benefits. The lack of reported safety data in this specific output limits comprehensive risk-benefit analysis. Future research should focus on validating these modeled projections with real-world evidence. Direct head-to-head randomized controlled trial data would provide higher certainty regarding comparative effectiveness and safety profiles in diverse clinical settings.